The Influence of Hypotensive Drugs on Mineral Status in Experimental and Clinical Studies
Nutritional Disorder, Hypertension, Mineral Deficiency
About this trial
This is an interventional treatment trial for Nutritional Disorder focused on measuring hypertension,, zinc, zinc supplementation, antihypertensive monotherapy, mineral status
Eligibility Criteria
Inclusion Criteria:
- informed written consent;
- age 18-65 years;
- primary hypertension;
- beginning monotherapy with an antihypertensive drug;
- stable body weight (less than 3 kg self-reported change during the three months prior to enrollment).
Exclusion Criteria:
- any secondary form of hypertension;
- the use of mineral supplements within the three months prior to enrollment;
- lipid disorders requiring treatment in the three months prior to the trial;
- a history of ischemic heart disease, stroke, congestive heart failure,
- clinically significant arrhythmia or conduction disorders, peripheral artery or vein disease, diabetes mellitus, abnormal renal, liver or thyroid gland function,
- clinically significant chronic or acute inflammatory process within the respiratory, genitourinary, or digestive tract, or in the oral cavity, larynx, pharynx, or in the paranasal sinuses, or connective tissue diseases, arthritis, or malignancy;
- infection in the month prior to enrollment,
- having an pacemaker implanted;
- alcohol, nicotine or drug abuse;
- mental disorders;
- pregnancy, childbirth or lactation at enrollment or in the three months prior to enrollment;
- or any other condition that, in the opinion of investigators, would make participation in the study not in the best interest of the subject, or could prevent, limit, or confound the efficacy of the study.
Sites / Locations
- Poznan University of Life Sciences
Arms of the Study
Arm 1
Arm 2
Arm 3
Active Comparator
Active Comparator
Active Comparator
group/arm C (control group)
group/arm D (diet group)
group/arm S (supplementation group)
Group C in the third stage (30 days) continued drug use with no change in diet and no mineral supplementation.
Group D in the third stage (30 days) received an optimal-mineral-content properly balanced diet enriched in food with high zinc content.
Group S in the third stage (30 days) received zinc supplementation as one capsule containing 15 mg of Zn taken orally once a day in the morning, two hours after antihypertensive drug administration with no change in diet.